Bio-Techne Reports Strong Growth in Q3 2025 Financials
Bio-Techne Announces Third Quarter Results for Fiscal 2025
Bio-Techne Corporation (NASDAQ: TECH) has revealed its impressive financial results for the third quarter. The company experienced notable growth in its revenues, showcasing resilience and strategic execution in a dynamic market landscape.
Highlights from Third Quarter FY2025
During the third quarter:
- Organic revenue soared by 6%, reaching $316.2 million, with a reported increase of 4%.
- GAAP earnings per share (EPS) stood at $0.14, a decrease from $0.31 in the previous year, while adjusted EPS improved to $0.56 from $0.48.
- The Protein Sciences segment saw a remarkable organic growth of 7%, bolstered by better conditions in the pharma market.
- Improved adjusted operating margins were recorded at 34.9%, a significant improvement driven by efficiency initiatives and increased volume.
Company Operational Performance
The leadership at Bio-Techne expressed satisfaction with the company's performance amid the evolving economic environment. Kim Kelderman, President and CEO, stated the team's consistent execution led to these strong results. The pharma market improvement, particularly from large partners, played a vital role in enhancing their cell therapy and protein analysis instrumentation business streams.
"Our team’s focus on maintaining profitability has propelled our adjusted operating margin to 34.9%, reflecting a substantial year-over-year increase," Kelderman noted.
Financial Measures and Revenue Growth Explanation
The revenue figures presented are in accordance with Generally Accepted Accounting Principles (GAAP). However, Bio-Techne also emphasizes non-GAAP measures such as adjusted diluted EPS and adjusted EBITDA, which provide deeper insights into the company’s operational performance.
The latest financial review indicated that:
- Adjusted EPS rose to $0.56, marking a solid increase from the prior year's $0.48.
- Adjusted operating income for this quarter increased by 11% compared to the previous year's numbers.
- Despite lower GAAP operating income affected by a non-recurring arbitration award, the adjusted profits reflect a positive trend in underlying operations.
Segment Performance Overview
Bio-Techne divides its operations into segments, primarily focusing on Protein Sciences and Diagnostics and Spatial Biology. Each segment’s performance has contributed to the overall positive results:
Protein Sciences Segment
This segment continues to be a leader in providing specialized proteins to biopharma and research fields. In the third quarter, net sales from this segment recorded $227.7 million, marking a 6% increase from the previous year. This growth is attributed partly to favorable market dynamics and product initiatives.
Diagnostics and Spatial Biology Segment
With a revenue increase to $89.2 million, up 2% from the same period last year, this segment maintains stability with consistent operating margins. The Diagnostics segment remains crucial for advancing diagnostic tools in various healthcare applications.
Commitment to Future Innovation
As Bio-Techne continues to navigate the challenges of the current market landscape, its strategic priorities lie in advancing scientific research and innovation. The company anticipates that ongoing investments and enhancement in its product portfolio will unlock further growth opportunities in the future.
For more insights, Bio-Techne will host a live earnings call to discuss its financial positions and strategic directions, inviting stakeholders to engage actively in the discourse.
Frequently Asked Questions
What is Bio-Techne Corporation?
Bio-Techne Corporation is a global life sciences company that provides innovative tools and bioactive reagents for the research and clinical diagnostic communities.
What were the highlights of Bio-Techne's Q3 2025 results?
In Q3 2025, Bio-Techne reported a 6% increase in organic revenue to $316.2 million, with an adjusted EPS of $0.56 indicating strong operational performance.
What segments does Bio-Techne operate in?
Bio-Techne operates primarily in two segments: Protein Sciences and Diagnostics and Spatial Biology, both of which have shown growth in recent quarters.
How does Bio-Techne measure financial performance?
Bio-Techne measures its performance using both GAAP and non-GAAP financial metrics to provide transparency and insight into its operational effectiveness.
Where can I find more information about Bio-Techne?
For more information, you can visit the official Bio-Techne website at biotechne.com.
About The Author
Contact Lucas Young privately here. Or send an email with ATTN: Lucas Young as the subject to contact@investorshangout.com.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.